3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

SCHEDULE 13G - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)

SCHEDULE 13D/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - Helix Acquisition Corp. II (0001869105) (Filer)

425 - Helix Acquisition Corp. II (0001869105) (Subject)

8-K - Helix Acquisition Corp. II (0001869105) (Filer)

10-Q - Helix Acquisition Corp. II (0001869105) (Filer)

SCHEDULE 13G/A - Helix Acquisition Corp. II (0001869105) (Subject)

SCHEDULE 13G - Helix Acquisition Corp. II (0001869105) (Subject)

424B3 - Helix Acquisition Corp. II (0001869105) (Filer)

Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity ("PIPE"), led by Cormorant Combining approximately $120 million from the former Helix II trust account (reflecting a final redemption rate of approximately 39% which is the second lowest redemption rate for a biotech de-SPAC transaction since 2022) with the PIPE provides approximately $382 million in gross proceeds Net proceeds will be used to accelerate the development of BBOT's pipeline of clinical-stage RAS-targeted oncology drug candidat

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate for a biotech de-SPAC transaction since 2022 BOSTON & SOUTH SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that Hel

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company ("SPAC") sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the "Registration Statement"), filed by Helix and BBOT, relating to the previously-announced b

Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity (PIPE) financing Leading institutional investors commit approximately $260 million through a PIPE led by Cormorant Asset Management Business combination is expected to be completed in the third quarter of 2025 The combined entity will be named BridgeBio Oncology Therapeutics (BBOT) and will be advancing a next-generation pipeline of therapies for patients with RAS and PI3Kα malignancies TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT"), a clinical-stage biopharmaceutical company advanci

SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

SC 13D - Helix Acquisition Corp. II (0001869105) (Subject)